Three groups of patients receiving oral anticoagulation treatment were evaluated. The groups consisted of patients with mechanical heart valve prosthesis (n = 60), patients after coronary bypass graft surgery (n = 60) and patients using oral anticoagulation after deep venous thrombosis or pulmonary embolism (n = 60).
Introduction
. . r u u the risk of major haemorrhage (10) . From the laboThere is wide acceptance that oral anticoagulants are ratory point of view, the final aim of oral anticoaeffective in the primary and secondary prevention of gulation is the reduction of thrombin generation to thromboembolic complications after deep venous such a level that fibrin can no longer be formed in thrombosis (1) , in patients with mechanical or bio-harmful quantities. logical heart valve prosthesis (2, 3) , after myocardial
. r .. ,Λ\ · ^ *· r * ι /c\ Λ Λ Several tests for the activation extent of the haemoinfarction (4) , in the prevention of stroke (5) and after . ., ,, , , ' j. /r\ -π. · * ·* c ι static system are now available, such as the measuremajor orthopaedic surgery (6) . The intensity of oral ' , . ., . , ' . , , . TTT -f i , r ,· ment of nbnnopeptide A, thrombin-antithrombin III anticoagulation however has been matter of discus-. .... * . " , «. « , . ," ox TT· t · · · complex (II), fibrin monomer as well as prothrombin sion for a long time (7, 8) . High-intensity anticoagu- t--^r ι · · (12, 13) and prothrombin fragment 1 + 2 (14) have major bleeding complications. Moderate-intensity an-^ ' « , j t j i · , .
XT-KTT,Γ ^ Λ ^ /-χ ι ι been shown to be dependent on the degree of antiticoagulation (INR 2.0 -2.5), however, may be . 11 rr *· -j-* j · i r · ι * · ι coagulation, equally effective, as indicated in several clinical trials in patients with bioprosthesis of the heart valve (2) A scheme of the relevant part of the coagulation and or after deep venous thrombosis (9) , and might lower fibrinolysis cascade is shown in figure 1 . The aim of this study was to establish the extent of prothrombin activation and its effect on thrombin activity in several patient groups receiving different degrees of oral anticoagulation treatment, and to compare the measured quantities (i. e. thrombin-antithrombin III, fibrin monomer, prothrombin fragment 1 -f 2) with regard to their usefulness as an index of thrombin activity during oral anticoagulation.
Materials and Methods

Methods
The 
Samples
Blood was collected between 9 and 11 a. m. in trisodium citrate (0.11 mol/l)-containing plastic tubes (9:1 by vol.). After centrifugation (1600g, 20 min, room temperature) the plasma was collected, analysed for the prothrombin time and after that immediately deep frozen at -70 °C until batch analysis of the specimens for the other analytes was performed. Before analysis they were thawed with tap water for 5 min just before use.
Results
In table 1 the medians and interquartile ranges of the investigated quantities are given for the group of healthy individuals. A thrombin-antithrombin III correlation with INR only was obtained in the group with mechanical heart valve prosthesis (r = -0.36, p = 0.004). 
Discussion
The intensity of oral anticoagulation has long been matter of discussion, and the problem always has been approached from a clinical standpoint. It is common opinion that the ultimate goal of treatment with oral anticoagulation is the prevention of thrombin formation or the reduction thereof to a level where no or nearly no thrombin generation occurs. Up to now the decreased activity of the coagulation system during anticoagulation treatment has been determined by measuring the prothrombin time as a global test for the extrinsic coagulation pathway. We have now used the relatively new assays for prothrombin fragment 1+2, thrombin-antithrombin III and fibrin monomer and tested them for their usefulness as markers of the effect of prothrombin activation and of thrombin activity during oral anticoagulation. Correlation studies between these coagulation activation markers and the INR show that only prothrombin fragment 1-1-2 decreases in all patient groups with the increase of the INR. Thrombin-antithrombin III decreased only in the group with mechanical heart valve prosthesis. The fibrin monomer concentrations showed no correlation in any patient group. Thus, prothrombin fragment 1+2 seems to be suited for the monitoring of the reduction of thrombin formation in patients under oral anticoagulation treatment.
The results in the patient group with mechanical heart valve prosthesis showed significantly decreased values for prothrombin fragment 1+2 and low normal thrombin-antithrombin III concentrations with increasing INR values. The actual median concentrations of prothrombin fragment 1 + 2 are located significantly below those of the lower limit of the reference group. Thus, thrombin formation is depressed to such a low level that from the laboratory point of view a prolonged period in the lowest INR category should not be a cause of concern in this patient group.
In the group of patients with coronary artery bypass grafts, only prothrombin fragment 1 + 2 values showed a decrease with increasing INR values. The median values of the different anticoagulation intensities are below the lower limit of the reference group and are somewhat higher than those in the group of patients with mechanical heart valve prosthesis. The prothrombin fragment 1+2 levels are also low in the group of patients receiving prophylactical treatment with oral anticoagulants after deep venous thrombosis and pulmonary embolism, and they also decrease with increasing INR. The question is whether the differences between the median values for prothrombin fragment 1 + 2 in the different intensity categories are an adequate index of the decrease of the thrombin. Considering the effect of oral anticoagulation in the three patient groups on the concentrations of prothrombin fragment 1+2, thrombin-antithrombin III and fibrin monomer, it appears that prothrombin fragment 1 + 2 is the most suitable for the measurement of the effect of oral anticoagulation. The test allows reliable measurements below the lower limit of the reference range; this is of interest especially in this study, which includes properly anticoagulated patients. On the basis of the concentrations measured for prothrombin fragment 1 + 2 it is clear that under stable anticoagulation the resulting thrombin activity is most depressed in the mechanical heart valve prosthesis and the deep venous thrombosis/pulmonary embolism group, followed by the coronary artery bypass graft group, but it is probably adequate in all groups. The thrombin-antithrombin III concentrations in the various patient groups and the different intensity categories of oral anticoagulation are less informative, although the median values are mostly in the lower quartile of the reference range. The fibrin monomer values are useless for the evaluation of the reduced thrombin activity under oral anticoagulation.
The median values are even higher in the patient groups than in the reference groups. The explanation for this is unclear, but there might be some interference in the test system. It is, however, also conceivable that the enhancement of the tissue plasminogen activator concentrations in anticoagulated patients, as we reported in a recent study (16) , also plays a role. Elevated tissue plasminogen activator concentrations could produce additional plasmin in the test system, which in turn would cause higher fibrin monomer values than expected.
In conclusion, from the three markers of coagulation activation used in this study, only the prothrombin fragment 1+2 concentrations showed full inverse parallelism with the INR levels. This has also been reported recently by Mannucci (17). The median prothrombin fragment 1+2 concentrations were strongly reduced in all patient groups, indicating satisfactory decrease of coagulation by oral anticoagulation treatment. The measurement of prothrombin fragment 1+2 seems to be appropriate in selected cases as an additional value for adjusting and monitoring the efficacy of anticoagulant therapy. This is important, because in general the question is whether the high intensities of oral anticoagulation are necessary for all indications as commonly recommended.
In several clinical studies less intense oral anticoagulation (2, 3, 5, 9, 18 -20) and other therapeutic regimens (1, (21) (22) (23) (24) (25) (26) have already been tested for the different indications of oral anticoagulation. Measurement of prothrombin fragment 1+2 might therefore be helpful in future clinical studies dealing with the efficacy of oral anticoagulation.
